Lyell Immunopharma, Inc. Research and Development Expense
Lyell Immunopharma, Inc. (LYEL) reported Research and Development Expense of $39.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Lyell Immunopharma, Inc. research and development expense for the quarter ending 2026-06-30 was $39.52M, a 13.39% increase year-over-year.
- Lyell Immunopharma, Inc. research and development expense for the quarter ending 2026-03-31 was $36.60M, a 15.75% decline year-over-year.
- Lyell Immunopharma, Inc. research and development expense for the quarter ending 2025-09-30 was $28.17M, a 28.68% decline year-over-year.
- Lyell Immunopharma, Inc. research and development expense for the quarter ending 2025-06-30 was $34.86M, a 13.42% decline year-over-year.
- Lyell Immunopharma, Inc. research and development expense for fiscal 2023 was $182.94M, a 14.92% increase from fiscal 2022.
- Lyell Immunopharma, Inc. research and development expense for fiscal 2022 was $159.19M, a 14.78% increase from fiscal 2021.
- Lyell Immunopharma, Inc. research and development expense for fiscal 2021 was $138.69M, a 23.90% decline from fiscal 2020.
- Lyell Immunopharma, Inc. research and development expense for fiscal 2020 was $182.24M, a 186.57% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.52M 10-Q · filed 2026-08-06 | $76.13M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $36.60M 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | $28.17M 10-Q · filed 2025-11-12 | $63.03M derived: sum of 2 quarters · filed 2026-08-06 | $106.48M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $34.86M 10-Q · filed 2026-08-06 | $78.30M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $43.45M 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $39.50M 10-Q · filed 2025-11-12 | $79.76M derived: sum of 2 quarters · filed 2025-11-12 | $122.94M 10-Q · filed 2025-11-12 | $169.93M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $40.26M 10-Q · filed 2025-08-12 | $83.44M 10-Q · filed 2025-08-12 | $130.43M derived: sum of 3 quarters · filed 2025-08-12 | $174.28M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $43.17M 10-Q · filed 2025-05-13 | $90.17M derived: sum of 2 quarters · filed 2025-05-13 | $134.02M derived: sum of 3 quarters · filed 2025-05-13 | $181.49M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $46.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $90.84M derived: sum of 2 quarters · filed 2024-11-07 | $138.31M derived: sum of 3 quarters · filed 2024-11-07 | $182.94M 10-K · filed 2024-02-28 |
| 2023-09-30 | $43.85M 10-Q · filed 2024-11-07 | $91.32M derived: sum of 2 quarters · filed 2024-11-07 | $135.95M 10-Q · filed 2024-11-07 | $173.98M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $47.47M 10-Q · filed 2024-08-07 | $92.10M 10-Q · filed 2024-08-07 | $130.13M derived: sum of 3 quarters · filed 2024-08-07 | $171.74M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $44.63M 10-Q · filed 2024-05-06 | $82.66M derived: sum of 2 quarters · filed 2024-05-06 | $124.27M derived: sum of 3 quarters · filed 2024-05-06 | $167.99M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $38.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $79.64M derived: sum of 2 quarters · filed 2024-02-28 | $123.36M derived: sum of 3 quarters · filed 2024-02-28 | $159.19M 10-K · filed 2024-02-28 |
| 2022-09-30 | $41.61M 10-Q · filed 2023-11-07 | $85.33M derived: sum of 2 quarters · filed 2023-11-07 | $121.16M 10-Q · filed 2023-11-07 | $140.44M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $43.72M 10-Q · filed 2023-08-08 | $79.55M 10-Q · filed 2023-08-08 | $98.83M derived: sum of 3 quarters · filed 2024-02-28 | $130.27M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $35.83M 10-Q · filed 2023-05-04 | $55.12M derived: sum of 2 quarters · filed 2024-02-28 | $86.55M derived: sum of 3 quarters · filed 2024-02-28 | $132.99M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $19.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $50.72M derived: sum of 2 quarters · filed 2024-02-28 | $97.16M derived: sum of 3 quarters · filed 2024-02-28 | $138.69M 10-K · filed 2024-02-28 |
| 2021-09-30 | $31.43M 10-Q · filed 2022-11-08 | $77.88M derived: sum of 2 quarters · filed 2022-11-08 | $119.41M 10-Q · filed 2022-11-08 | $154.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $46.45M 10-Q · filed 2022-08-04 | $87.97M 10-Q · filed 2022-08-04 | $123.06M derived: sum of 3 quarters · filed 2023-02-28 | $147.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $41.53M 10-Q · filed 2022-05-10 | $76.62M derived: sum of 2 quarters · filed 2023-02-28 | $101.12M derived: sum of 3 quarters · filed 2023-02-28 | $198.27M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $35.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $59.59M derived: sum of 2 quarters · filed 2023-02-28 | $156.74M derived: sum of 3 quarters · filed 2023-02-28 | $182.24M 10-K · filed 2023-02-28 |
| 2020-09-30 | $24.50M 10-Q · filed 2021-11-12 | $121.65M derived: sum of 2 quarters · filed 2021-11-12 | $147.15M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $97.15M 10-Q · filed 2021-08-12 | $122.65M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $63.59M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |